BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38143338)

  • 1. Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.
    Jia X; Zhang T; Lv X; Du H; Sun Y; Guan Y
    Cancer Biomark; 2023; 38(4):523-535. PubMed ID: 38143338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3.
    Kong C; Zheng L; Fang S; Chen M; Lin G; Qiu R; Zhao Z; Chen W; Song J; Yang Y; Ji J
    Technol Cancer Res Treat; 2023; 22():15330338231195494. PubMed ID: 37650153
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel signature model based on mitochondrial-related genes for predicting survival of colon adenocarcinoma.
    Gao H; Xing F
    BMC Med Inform Decis Mak; 2022 Oct; 22(1):277. PubMed ID: 36273131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification prognosis-associated immune genes in colon adenocarcinoma.
    Miao Y; Wang J; Ma X; Yang Y; Mi D
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33140821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
    Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
    Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucose metabolism-based signature predicts prognosis and immunotherapy strategies for colon adenocarcinoma.
    Bai Z; Yan C; Nie Y; Zeng Q; Xu L; Wang S; Chang D
    J Gene Med; 2024 Jan; 26(1):e3620. PubMed ID: 37973153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment.
    Lin A; Gu T; Hu X; Zhang J; Luo P
    J Immunol Res; 2022; 2022():8179799. PubMed ID: 35707003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
    Wang H; Wang W; Wang Z; Li X
    Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity.
    Huang X; Cao Y; Bao P; Zhu B; Cheng Z
    Cancer Med; 2023 Jan; 12(1):837-851. PubMed ID: 35634680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactate Metabolism-Associated lncRNA Pairs: A Prognostic Signature to Reveal the Immunological Landscape and Mediate Therapeutic Response in Patients With Colon Adenocarcinoma.
    Xiao J; Wang X; Liu Y; Liu X; Yi J; Hu J
    Front Immunol; 2022; 13():881359. PubMed ID: 35911752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a 5-mRNAsi-related gene signature to predict the prognosis of colon adenocarcinoma.
    Huang H; Lu L; Li Y; Chen X; Li M; Yang M; Huang X
    PeerJ; 2023; 11():e16477. PubMed ID: 38025763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma.
    Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J
    Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203
    [No Abstract]   [Full Text] [Related]  

  • 16. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of microsatellite instability and immune-related prognostic biomarkers in colon adenocarcinoma.
    Sun Z; Li G; Shang D; Zhang J; Ai L; Liu M
    Front Immunol; 2022; 13():988303. PubMed ID: 36275690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
    Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
    Front Immunol; 2021; 12():665002. PubMed ID: 34367132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Four-Gene Metabolic Signature to Evaluate the Prognosis of Colon Adenocarcinoma Patients.
    Zheng Y; Wu R; Wang X; Yin C
    Front Public Health; 2022; 10():860381. PubMed ID: 35462848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.